mylan

Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Some chief executive officers were among the insiders making notable purchases this past week. Insiders made return trips to the buy window to increase their stakes, and one took advantage of a...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included an old-school conglomerate and a social media pair. Bearish calls included an electric car maker and a pharmaceutical firm. Another major hurricane slammed into the United States this past...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured giants in the consumer electronics and entertainment arenas. Bearish calls included discount retailers and a social media leaders. The new year is off to a strong start in the equity...

The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In September, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has lost 0.44...

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its...

Mylan NV (NASDAQ: MYL) faced its fair share of controversy earlier this year for increasing the price of its potentially life-saving EpiPen product by more than 400 percent over the past few years. On Friday, Mylan announced the launch of the authorized generic for EpiPen at a wholesale acquisition...

Mylan NV (NASDAQ: MYL) CEO Heather Bresch told a U.S. congressional committee last week that the company makes a profit of around $100 for each package of EpiPen it sells. Bresch testified in front of the committee amid a scandal in which Mylan may have unjustifiably raised the price of its...

Bill George, a Harvard Business School senior fellow and ex-chairman of Medtronic PLC (NYSE: MDT) has some harsh words for Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch. Speaking as a guest on CNBC's "Squawk On The Street" on Wednesday, George said that Bresch could be in for a "rough time" as she is...

Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch could face the wrath of the U.S. Congress on Wednesday given the company's practice of boosting the price of its potential life-saving EpiPen. According to a Bloomberg report, Robert Coury, Bresch's boss, won't be taking the stand on Wednesday. Coury,...

Biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) is "making progress" in developing a less costly alternative to Mylan NV (NASDAQ: MYL)'s EpiPen. According to Connecticut-based News Times, MannKind's local manufacturing facility employs around 150 people in the city and plays a key...

Mylan NV (NASDAQ: MYL), the seller of a potentially life-saving medical device called EpiPen, saw its share of controversy this week when officials of the U.S. government called into question the company's pricing policies. In 2008, the EpiPen sold for around $100 but has since risen six...

Mylan NV (NASDAQ: MYL)'s 400 percent price hike to a potentially life-saving device was called into question by members of the U.S. government this week. Mylan, the maker of EpiPen, an epinephrine auto injector used in emergency cases by individuals suffering a severe allergic reaction,...

Mylan NV (NASDAQ: MYL) is the latest pharmaceutical company to come under government scrutiny. Mylan is the maker of a device that provides epinephrine in the event of anaphylaxis — also known as the EpiPen. According to Fortune, Mylan built the EpiPen from a "weakening enterprise" in 2007 to...

Upcoming earnings highlights include the latest results from two generic pharmaceutical giants. Wall Street analysts are looking for earnings growth from just one of them. However, sequentially higher revenues are anticipated from both companies. On Tuesday, international generic pharmaceutical...